Investor Presentation - Q2 & H1FY27,

Windlas Biotech Limited Reg. Off.: 40/1, Mohabewala Industrial Area Dehradun, Uttarakhand 248 110, India Tel.:+91-135-6608000-30, Fax:+91-135-6608199 Corp. Off.: 705-706, Vatika Professional Point, Sector-66, Golf Course Ext. Road, Gurgaon, Haryana 122 001, India Tel.:+91-124-2821030 CIN-L74899UR2001PLC033407 November 5, 2026 To To Listing / Compliance Department Listing / Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street, Mumbai – 400 001 Bandra Kurla Complex Bandra (E), Mumbai – 400 051 BSE CODE: 543329 NSE SYMBOL: WINDLAS Dear Sir/ Madam, Sub: Regulation 30(6) of SEBI (LODR) Regulations, 2015 Please find enclosed herewith the Investor Presentation – Q2 & H1FY27, for your record. Kindly take the same on record. Thanking you, Yours faithfully, For Windlas Biotech Limited Ananta Narayan Panda Company Secretary & Compliance Officer Encl: as above www.windlas.com Windlas Biotech Limited Investor Presentation – Q2 & H1FY27 Disclaimer This presentation and the accompanying slides (the “Presentation”), has been prepared by Windlas Biotech Limited (the “Company”), solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward- looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. The Company and/or its affiliated companies and/or their respective employees and/or agents have no responsibility or liability (express or implied) whatsoever and howsoever arising (including, without limitation for any claim, proceedings, action, suits, losses, expenses, damages or costs) which may be brought against or suffered by any person as a result of acting in reliance upon the whole or any part of the contents of this presentation and neither the Company, its affiliated companies nor their respective employees or agents accepts any liability for any error, omission or misstatement, negligent or otherwise, in this presentation and any liability in respect of the presentation or any inaccuracy therein or omission therefrom which might otherwise arise is hereby expressly disclaimed. Table of Contents Windlas – At a Glance Q2 & H1FY27 Highlights SCALABILITY, DURABILITY & Business Verticals PROFITABILITY Company Overview Annual Financials Windlas – Trusted Partner in Delivering Value Across the Healthcare Ecosystem Building Scale and Excellence in ~25 Years of Expertise Robust Financial Position Generic Formulations Creating Strong Entry Barriers (as of FY26) • Presence across all stages of Generics Value Chain • 5 State-of-the-Art, WHO-GMP compliant manufacturing • CAGR FY22 to FY26 with focus on Formulations - Development, plants with 8,522 Mn of capacity for Tablets & Capsules, 54 • 18% Revenue Manufacturing and Marketing Mn for Pouch & Sachets & 61 Mn for Liquid Bottles • 19% EBITDA • 8 of the Top 10 and 15 of the Top 20 Indian • DSIR approved R&D laboratory & pilot scaled equipment • 15% PAT Pharma Companies serviced • 29% ROE* and 32% ROCE* • IP Rights (Formulation Technology) across 99% of • 926 Customers served products sold • 4.7x Asset Turnover# • 5,644 Brands catered to across therapeutic areas • Higher revenue share of Chronic & Sub-Chronic (53%) and • Rs. 251 Cr of Strong Net Liquidity and Net Debt free Complex Generic (74%) in overall product portfolio • Fast growing in Trade Generics and Exports • Rs. 104 Cr of Cashflow from Operations • 4,393 brands in Complex Generics • 546 Brands under Domestic Trade Generics • A+ Stable ICRA Rating • Strong Dossier development and regulatory expertise • 67 Products exported across 10 Countries • Proficient Leadership Team • Long standing Customer Relationships *For ROCE & ROE, Capital Employed & Equity at the end of period after removing cash/bank & mutual fund balances at the end of period; # Excluding CWIP of Plant- 6. Q2 & H1FY27 Highlights Management Commentary The Indian Pharmaceutical Market (IPM) reported volume growth of 2.3% during the quarter. Windlas Biotech extending its track record to 15 consecutive quarters of record revenue with 19% YoY growth to Rs. 264 crore. Each of our three businesses plays a distinct role in our growth story. Generic Formulations CDMO remains our anchor: customers have entrusted us with a larger share of their portfolios and new products, which lifted Q2FY27 revenue by 34% to Rs. 264 crore and H1 FY27 revenue by 32% to Rs. 422 crore. In Trade Generics & Institutional, we have used this period to reshape the portfolio, replacing codeine-based products with new launches that give the business a broader and more resilient base. This vertical generated revenue Rs. 36 crore in Q2FY27 and Rs. 66 crore in H1FY27. Export markets have longer lead times. We continue to focus on investments in dossiers, product registrations and site approvals with few turning into commercial supplies resulting in Q2FY27 revenue growth 26% to Rs. 12 crore and H1FY27 revenue growth 46% Mr. Hitesh Windlass to Rs. 23 crore. Together, these give us a deeper customer base, a stronger portfolio and a growing geographical presence. Chairman & Managing Director We remain committed to creating long-term value for our shareholders. The company reported its highest ever earnings per share (EPS) of Rs. 17.21 in H1FY27. In line with our dividend policy and commitment to shareholder returns, the company paid dividend Rs. 13 crores (Rs. 6.3 per share) related to FY26. With the Rs. 47 crore buyback successfully completed without promoter participation, the dividend paid and capex funded from our own resources, we closed the half-year with healthy net liquidity of Rs. 223 crore, a balance sheet that supports both shareholder returns and growth. The opportunities ahead of us are significant, and we approach them with confidence, humility, and determination. Backed by dedicated team and the commitment to excellence, we are focused on building a stronger Windlas Biotech that creates lasting value for patients, partners, employees and shareholders alike. Management Commentary Consistency is not the most exciting word in business, but it is the one our customers & shareholders value the most. In H1 FY27, Windlas crossed Rs. 500 crore in half-yearly revenue for the first time. Revenue grew 19% YoY to Rs. 264 crore in Q2 FY27 and 18% to R [Showing first 8,000 characters — download PDF for full document]